CR8646A - Sintesis regioespecifica de derivados de ester-42 de rapamicina - Google Patents

Sintesis regioespecifica de derivados de ester-42 de rapamicina

Info

Publication number
CR8646A
CR8646A CR8646A CR8646A CR8646A CR 8646 A CR8646 A CR 8646A CR 8646 A CR8646 A CR 8646A CR 8646 A CR8646 A CR 8646A CR 8646 A CR8646 A CR 8646A
Authority
CR
Costa Rica
Prior art keywords
ester
regiospecifica
rapamicina
steresis
derivados
Prior art date
Application number
CR8646A
Other languages
English (en)
Inventor
Jianxin Gu
Ping Cai
Mark E Ruppen
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34965235&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR8646(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR8646A publication Critical patent/CR8646A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Se describe un metodo para la sintesis regioespecifica de derivados de ester 42 de rapamicina; el metodo involucra la acilacion catalizada por lipasa de rapamicinca 42- hidroxi con un donante acilo como ester vinilico, un ester isopropenilico o un anhibrido en un solvente organico adecuado.
CR8646A 2004-04-14 2006-09-21 Sintesis regioespecifica de derivados de ester-42 de rapamicina CR8646A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56192604P 2004-04-14 2004-04-14

Publications (1)

Publication Number Publication Date
CR8646A true CR8646A (es) 2007-08-28

Family

ID=34965235

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8646A CR8646A (es) 2004-04-14 2006-09-21 Sintesis regioespecifica de derivados de ester-42 de rapamicina

Country Status (23)

Country Link
US (1) US7268144B2 (es)
EP (1) EP1737869A1 (es)
JP (1) JP4224115B2 (es)
KR (1) KR20070015544A (es)
CN (1) CN1942476A (es)
AR (1) AR049019A1 (es)
AU (1) AU2005238431A1 (es)
BR (1) BRPI0509852A (es)
CA (1) CA2562952A1 (es)
CL (1) CL2008000507A1 (es)
CR (1) CR8646A (es)
EC (1) ECSP066927A (es)
GT (1) GT200500085A (es)
IL (1) IL178315A0 (es)
MX (1) MXPA06011881A (es)
NO (1) NO20065090L (es)
PA (1) PA8629901A1 (es)
PE (1) PE20060253A1 (es)
RU (1) RU2387657C2 (es)
SG (1) SG152234A1 (es)
TW (1) TW200536542A (es)
UA (1) UA87492C2 (es)
WO (1) WO2005105811A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2344821C2 (ru) 2002-07-30 2009-01-27 Уайт Парентеральные композиции, содержащие гидроксиэфиры рапамицина
PL1735321T3 (pl) * 2004-04-14 2009-04-30 Wyeth Corp Proces wytwarzania 42-estrów rapamycyny i 32-estrów FK-506 z kwasem dikarboksylowym, prekursory koniugatów rapamycyny oraz przeciwciała
CN1946852A (zh) * 2004-04-27 2007-04-11 惠氏公司 利用雷帕霉素特异性甲基化酶标记雷帕霉素
TW200616633A (en) * 2004-08-10 2006-06-01 Wyeth Corp CCI-779 derivatives and methods of making same
JP2008530090A (ja) * 2005-02-09 2008-08-07 ワイス Ｃｃｉ−７７９多形及びその使用
US7538119B2 (en) * 2005-11-04 2009-05-26 Wyeth 41-Methoxy isotope labeled rapamycin 42-ester
JP2009518648A (ja) * 2005-12-07 2009-05-07 ワイス 結晶性ラパマイシンを調製するための方法およびを示差走査熱量測定使用してラパマイシン化合物の結晶化度を測定するための方法
PE20070748A1 (es) * 2005-12-07 2007-08-08 Wyeth Corp Proceso ajustable a escala para la preparacion de un 42-ester de rapamicina a partir de un boronato de 42-ester de rapamicina
AR058282A1 (es) * 2005-12-07 2008-01-30 Wyeth Corp Forma cristalina purificada de cci-779, un proceso para la preparacion del mismo, un metodo para monitorear la cristalizacion del cci-779, un kit y una composicion farmaceutica que lo comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer.
CA2644156A1 (en) * 2006-03-07 2007-09-13 Wyeth Process for preparing water-soluble polyethylene glycol conjugates of macrolide immunosuppressants
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
TW200845960A (en) * 2007-04-05 2008-12-01 Wyeth Corp Wortmannin-rapalog conjugate and uses thereof
US20090253733A1 (en) * 2008-04-02 2009-10-08 Biointeractions, Ltd. Rapamycin carbonate esters
WO2009131631A1 (en) * 2008-04-14 2009-10-29 Poniard Pharmaceuticals, Inc. Rapamycin analogs as anti-cancer agents
CN101676291B (zh) * 2008-09-18 2012-05-09 上海海和药物研究开发有限公司 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途
CA2937492C (en) 2008-11-11 2019-08-13 The Board Of Regents Of The University Of Texas System Inhibition of mammalian target of rapamycin
IT1394309B1 (it) * 2009-05-22 2012-06-06 Poli Ind Chimica Spa Nuovo approccio chimico-enzimatico alla sintesi del pimecrolimus
US10391059B2 (en) 2009-11-11 2019-08-27 Rapamycin Holdings, Inc. Oral rapamycin nanoparticle preparations and use
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
RU2603261C2 (ru) * 2011-04-01 2016-11-27 Сандоз Аг Региоселективное ацилирование рапамицина в положении с-42
US10751450B2 (en) 2012-06-08 2020-08-25 Biotronik Ag Rapamycin 40-O-cyclic hydrocarbon esters, compositions and methods
CN104203959B (zh) * 2012-06-08 2017-09-15 百多力股份公司 雷帕霉素40‑o‑环状烃酯、组合物和方法
US20160030401A1 (en) 2013-03-13 2016-02-04 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors for prevention of intestinal polyp growth and cancer
CN108864149B (zh) 2013-03-15 2022-04-05 生物传感器国际集团有限公司 雷帕霉素衍生物的纯化
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
WO2017190145A1 (en) 2016-04-29 2017-11-02 Icahn School Of Medicine At Mount Sinai Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
CN110446495B (zh) 2017-02-17 2023-09-05 特维娜有限公司 含有7元氮杂杂环的δ阿片受体调节化合物及其使用和制备方法
EP3848065B1 (en) 2017-05-15 2023-07-26 C. R. Bard, Inc. Medical device with drug-eluting coating and intermediate layer
JP7357629B2 (ja) * 2017-11-20 2023-10-06 アイカーン スクール オブ メディスン アット マウント サイナイ 治療用ナノバイオロジー組成物での訓練された免疫の阻害
JP7262581B2 (ja) 2018-11-14 2023-04-21 ルトニックス，インコーポレーテッド 改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス
CN113939324A (zh) 2019-04-08 2022-01-14 巴德外周血管股份有限公司 在经改性装置表面上具有药物洗脱涂层的医疗装置
CN116406268A (zh) 2020-10-27 2023-07-07 特维娜有限公司 δ-阿片样物质调节剂的结晶和无定形形式
WO2022128810A1 (en) * 2020-12-14 2022-06-23 Biotronik Ag Materials and methods for treating viral and other medicinal conditions
CN118459539B (zh) 2021-03-19 2026-01-06 生物治疗探索股份有限公司 用于调节训练免疫的化合物及其使用方法
WO2023070605A1 (en) * 2021-10-29 2023-05-04 Trevena, Inc. Methods of preparing 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds
CN118027062B (zh) * 2023-11-03 2025-02-14 沈阳药科大学 一种雷帕霉素前药及其纳米制剂的制备和应用
GB202415232D0 (en) 2024-10-16 2024-11-27 Nacamed As Composition

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4650803A (en) 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5210030A (en) * 1990-06-25 1993-05-11 Merck & Co., Inc. Process for selectively acylating immunomycin
PT98990A (pt) * 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5233036A (en) 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5260300A (en) 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
TWI256395B (en) * 1999-09-29 2006-06-11 Wyeth Corp Regioselective synthesis of rapamycin derivatives
US6277983B1 (en) 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
JP2004509898A (ja) 2000-09-19 2004-04-02 ワイス 水溶性ラパマイシンエステル
RU2344821C2 (ru) 2002-07-30 2009-01-27 Уайт Парентеральные композиции, содержащие гидроксиэфиры рапамицина
JP4227649B2 (ja) 2003-08-07 2009-02-18 ワイス Ｃｃｉ−７７９の位置選択的合成
EP1660081A1 (en) 2003-09-03 2006-05-31 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and pharmaceutical compositions containing the same
DE602004011398T2 (de) * 2004-01-08 2009-01-15 Wyeth Direkt komprimierbare pharmazeutische zusammensetzung für die orale verabreichung von cci-779

Also Published As

Publication number Publication date
TW200536542A (en) 2005-11-16
AU2005238431A1 (en) 2005-11-10
US7268144B2 (en) 2007-09-11
NO20065090L (no) 2006-11-13
ECSP066927A (es) 2006-12-20
US20050234234A1 (en) 2005-10-20
SG152234A1 (en) 2009-05-29
RU2387657C2 (ru) 2010-04-27
EP1737869A1 (en) 2007-01-03
CL2008000507A1 (es) 2008-07-04
BRPI0509852A (pt) 2007-10-23
GT200500085A (es) 2005-11-03
WO2005105811A1 (en) 2005-11-10
JP2007532134A (ja) 2007-11-15
RU2006134014A (ru) 2008-05-20
PE20060253A1 (es) 2006-03-30
UA87492C2 (en) 2009-07-27
CN1942476A (zh) 2007-04-04
JP4224115B2 (ja) 2009-02-12
MXPA06011881A (es) 2006-12-14
IL178315A0 (en) 2007-02-11
PA8629901A1 (es) 2006-06-02
CA2562952A1 (en) 2005-11-10
KR20070015544A (ko) 2007-02-05
AR049019A1 (es) 2006-06-21

Similar Documents

Publication Publication Date Title
PA8629901A1 (es) Sintesis regioespecifica de derivados de 42-ester de rapamicina
AR049853A1 (es) Sistema y metodo para optimizar la produccion animal en base a la incorporacion de nutrientes ambientales
ES2492497T3 (es) Perácidos alfa-ceto y métodos para su producción y uso
BRPI0815750A2 (pt) processo para recuperar um solvente orgânico e um etanol orgânico de uma mistura de etanol/água.
CL2008003698A1 (es) Compuestos derivados de imidazo[1,2-a]piridina e imidazo[1,2-b]piridazina, inhibidores de la btk; composicion farmaceutica que los comprende; y uso para el tratamiento de un estado patologico inflamatorio y/o autoinmune tal como la artritis reumatoide.
AR106156A2 (es) Un procedimiento para preparar una composición de curado fuera de un procedimiento de curado de carne, una composición de curado obtenible mediante dicho procedimiento, y un procedimiento para conservar una carne o un producto a base de carne
CR10256A (es) Soporte estructural
SV2005002082A (es) "prolina cci-779, produccion y usos de la misma, y síntesis enzimática de dos etapas de prolina cci-779 y cci-779" ref. am-101578salvo
CL2012000588A1 (es) Método de tratamiento de semilla que comprende poner en contacto la semilla con una composición que comprende una mezcla compleja agrícolamente aceptable de material orgánico disuelto caracterizado por material orgánico natural que es parcialmente humificado.
MX2007010296A (es) Procedimiento para la degradacion por metatesis de cauchos nitrilicos.
MX9207085A (es) Un procedimiento de esterificacion catalizado.
CR20120340A (es) Sistema de gasificación
CY1108654T1 (el) Μεθοδος καθαρισμου της διακερεϊνης
BRPI0817826A2 (pt) Formulações herbicidas de éster de fluroxipir meptila com c4-c8 ésteres de triclopir, 2,4-d ou mcpa isentas de solvente aromático.
WO2008045185A3 (en) Process for the preparation of long-chain retinyl esters from short-chain retinyl esters and long-chain acids or long-chain esters employing lipases in organic solvents
CR8074A (es) Triazolopyrimidinas
AR051341A1 (es) Proceso para la preparacion de derivados de [1,4,5]-oxadiazepina
ECSP077384A (es) Compuestos tricíclicos que contienen heteroátomos
WO2006105082A3 (en) Alkane oxidation by modified hydroxylases
ECSP077505A (es) Proceso para mejorar y recuperar hidrocarburos residuales, pesados y extrapesados
CU23770A3 (es) Proceso y sistema para mejorar y recuperar hidrocarburos residuales, pesados y extrapesados
FI20050708A0 (fi) Menetelmä polystyreenin kierrättämiseksi
AR050605A1 (es) Proceso para la preparacion de aceites vegetales hidroxi-funcionales
AR064507A1 (es) Nuevas formas solidas cristalinas de forma base de o-desvenlafaxina
RU2003119992A (ru) Способ получения 1,2,3,4-тетрахлоргексафторбутана

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)